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functions pre-infusion and at different points post-DLI (D11,
30, 60, 90, 360) in ﬁve patients with CP-CML who re-
lapsed after allogeneic BMT. In three patients who achieved he-
matological and cytogenetic remission after DLI we observed a
statistically signiﬁcant increase in the percentage and absolute
numbers of CD8 and CD56 lymphocytes, in the percentage of
activation markers on T and NK cells (CD3/DR, CD3/CD25 and
CD56/DR), of lymphocytes producing IL-2 or interferon-gamma,
in NK activity and in non-stimulated lymphocyte proliferation.
These changes were not observed in two patients who did not
achieve complete remission after DLI. The percentage of apopto-
tic markers (Fas, FasL and Bcl-2) on lymphocytes or CD34 cells
did not change after DLI. Taken together, these preliminary re-
sults suggest that the therapeutic effect of DLI on CP-CML is
mediated by classical cytotoxic and proliferative events involving T
and NK lymphocytes.
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OVERLAPPING IMMUNE RESPONSES IN DONOR LYMPHOCYTE INFU-
SION (DLI)-ASSOCIATED GRAFT-VS-HOST DISEASE
Hess, A.D., Miura, Y., Bright, E.C., Thoburn, C.J., Vogelsang, G.B.
The Johns Hopkins University, Baltimore, MD.
Infusion of donor lymphocytes (DLI) is a viable approach to
eliminate residual tumor cells following non-myeloablative stem
cell transplantation (SCT). Following DLI, severe GVHD often
develops with a rapid onset and can include elements of both acute
and chronic GVHD. Interestingly, type 1 and 2 cytokines play a
major role in acute and chronic GVHD, respectively, To further
explore the pathophysiology of DLI-associated GVHD, IL-10 and
gamma interferon (IFN) cytokine proﬁles were assessed in periph-
eral blood lymphocytes (PBL) and skin biopsies from patients with
GVHD after myeloablative SCT and after Donor Lymphocyte
Infusion (DLI) following non-myeloablative SCT. PBL and skin
were analyzed for IL-10 and IFN mRNA transcripts by real-time
quantitative RT-PCR(Table 1). Patients with SCT-GVHD exhib-
ited higher levels of IFN	 mRNA transcripts (compared to tran-
scripts for IL-10) in the skin with the IL-10/IFN ratio less than 1.
Interestingly, the levels of cytokine message in the skin were much
greater than the levels detected in PBL, ﬁndings consistent with
the enrichment of activated T cells in the target tissue. Compar-
atively, patients with DLI-GVHD had a greater proportion of
IL-10 mRNA transcripts in the target tissue with IL-10/IFN	
ratios 5. The dominance of IL-10 was similar to the observations
in autologous GVHD where IL-10 mRNA levels were 6-fold
higher in patients with clinical evidence of disease. The results
suggest that there are distinct patterns of cytokine expression in
patients with DLI-GVHD that may reﬂect Th2-drived mecha-
nisms that overlap inthe acute phase of GVHD. Consistent with
this hypothesis is T cell receptor V spectratype analysis of the
target tissue. Although initial analysis indicates a broad spectrum of
T cells inﬁltrating the target tissue, subsets of T cells expressing a
few V T cell receptor genes persisted in both acute and chronic
phases of GVHD. Evaluation of the cytokine proﬁle within the
tissue provides important insights into the pathogenesis of DLI-
GVHD.
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ALLOGENEIC MEMORY RESPONSE CONTRIBUTES TO THE PERSIS-
TENCE OF ALLORECTIVE T CELLS FOR MEDIATING GRAFT-VERSUS-
HOST DISEASE
Zhang, Y., Jeo, G., Zhu, J., Emerson, S.G. Departments of Medicine,
Pediatrics, University of Pennsylvania School of Medicine, Philadelphia,
PA.
GVHD evolves over weeks to months following allogeneic bone
marrow transplantation (allo-BMT). While persistent alloreactive
T cells in vivo are believed to be essential for GVHD development,
the relative role of effector versus memory T cells in sustaining
tissue injuries remains unknown. Using a major histocompatibility
complex-identical minor antigen-mismatched mouse model, we
now report that infusion of C3H.SW CD8 T cells into B6 mice
induces both typical primary and memory-like immune responses
in recipients. We found that B6 mice receiving C3H.SW CD8 T
cells developed clinical sign of GVHD by day 21 following allo-
BMT and about 60% of them died by day 55 due to GVHD. In
parallel, alloreactive CD8 T cells secreting IFN-g peaked in the
liver of B6 mouse receiving C3H.SW CD8 T cells by day 14
(0.520.048X105), declined by day 28 (0.0550.031X105), and
increased again by day 42 (0.2880.012X105) after transplanta-
tion. A similar biphasic pattern of alloreactive CD8 T cell expan-
sion was also observed in the spleens of these B6 mice. The decline
in alloreactive T cells was accompanied with increased Annexin
V-positive donor CD8 T cells in the spleens (10.13.1% at day 21
vs. 4.53.0% at day 14) and livers (9.02.3% at day 21 vs.
3.71.2% at day 14) of these B6 recipients. Interestingly, donor
CD8 T cells recovered from B6 mice receiving C3H.SW CD8 T
cells at days 42 after allo-BMT expressed low levels of CD25 but
high levels of CD44 and CD122, and contained at least two distinct
subsets:CD62Llo and CD62Lhi CD8 T cells. Both the CD62Llo
and CD62Lhi CD8 T cells were able to rapidly produce high levels
of IFN-g ex vivo, corresponding to effector memory and central
memory CD8 T cells, respectively. When each population was
separately transferred along with C3H.SW T cell-depleted BM
into irradiated secondary B6 mice, both CD62Lhi and CD62Llo
CD8 T cells survived and vigorously expanded in the secondary
recipients. As the result, 70% of these secondary B6 mice died of
GVHD by day 35. Notably, as few as 0.075X106 of CD62Lhi CD8
central memory T cells recovered from primary B6 mice with
GVHD at days 42 after allo-BMT were sufﬁcient to induce lethal
GVHD in 67.5% B6 mice. In comparison, administration of
0.5X106 C3H.SW CD44loCD62Lhi naı¨ve CD8 T cells only in-
duced lethal GVHD in 30% of B6 mice. These ﬁndings indicate
that allogeneic memory T cell responses may be responsible for the
persistence of alloreactive T cells mediating tissue injuries.
Table. Cytokine mRNA Transcripts in PBLs and Target Tissue
Sample
No.
Sample
Source IL-10 IFN
IL-10/
IFNRatio
0 Controls
(n  10)
PBL 0.66 1.41 0.5
1 DLI PBL 0.3 14.8 0.02
Skin 2.8 0.2 14.0
2 DLI PBL 9.8 29.6 0.3
Skin 44.8 3.1 14.5
3 DLI PBL 8.5 0.9 9.4
Skin 25.8 4.9 5.3
4 DLI PBL 167.5 1 167.0
Skin 12.9 1 13.0
5 MHC Matched—
Related
PBL 3.9 0.7 5.6
Skin 103.1 3571.0 0.03
6 MHC Mismatch—
Related
PBL 7.9 19.5 0.4
Skin 63.3 78.1 0.8
7 MHC Matched—
Unrelated
PBL 126.7 12.9 9.8
Skin 2.4 1887.0 0.001
8 MHC Matched—
Unrelated
PBL 51.5 4.6 11.0
Skin 3.9 15.9 0.24
9 MHC Matched—
Related
PBL 29.6 27.6 1.1
Skin 51.5 136.0 0.38
Relative transcripts normalized against the housekeeping gene GAPDH (1/(CT cyto-
kine-CT GAPDH)2  104.
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